At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 89 enrolled
Drug / intervention
Probiotic +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Controlled Trial of Lactobacillus Rhamnosus GG to Promote Intestinal Health
In Brief
A Phase 4 clinical trial evaluating Probiotic and Placebo for Communicable Diseases and 4 related conditions. Completed, enrolled 89 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the effectiveness of bacteria called Lactobacillus GG, a Probiotic, in preventing the growth of resistant bacteria in the digestive tract in patients on broad spectrum antimicrobials.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCommunicable Diseases, Infection, Anti-Infective Agents, Therapeutic Uses, Pharmacologic Actions
CountriesUnited States
CollaboratorsCenters for Disease Control and Prevention
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartJan 2014
First PostedJan 2014
Primary CompletionOct 2015
Study CompletionDec 2018
TodayJul 2026
First PostedJan 27, 2014
Enrollment StartJan 1, 2014
Primary CompletionOct 1, 2015
Study CompletionDec 1, 2018
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 12.4 years ago
Interventions
Probioticdietary
1 capsule containing 10 billion cells of Lactobacillus rhamnosus GG on a twice-daily basis
Placeboother
Sugar pill